Market Scope
Market Research Future (MRFR) expects the Antihypertensive Drugs Market to touch a valuation of USD 41,123.2 Million by 2023. MRFR also anticipates the global market to procure a growth rate of 2.73% between 2015 and 2023 (evaluation period).
Major Boosters and Impediments
The heightened rate of cardiovascular disorder rate worldwide, due to evolving demographics and the surge in stroke, and diabetic patients can favor the antihypertensive drugs market in the following years. Moreover, the blossoming elderly population in emerging regions, with reports suggesting a growth of 154% from 2017 to 2050, crossing 1.6 billion by 2050, should also push the demand for antihypertensive drugs. Another growth booster can be the accelerated number of baby boomers prone to a variety of age-related ailments across various countries.
Large-scale funding by the government as well as charitable trusts for stroke prevention, treatment and research in developed countries is likely to bolster the demand for antihypertensive drugs in the ensuing years. The Patient-Focused Drug Development initiative in the United States throws light on the significance of better patient care, helping understand the severity of hypertension and its impact on the patients’ life. People are growing more aware about the treatment options available for hypertension, especially due to these sorts of initiatives that are striving to boost the education level.
Request For Free Sample Copy : https://www.marketresearchfuture.com/sample_request/2347
Segmental Status
Therapeutic class, type and distribution channels are the key segments outlined in the market study of anti-hypertensive drugs.
The anti-hypertensive drugs market, with respect to therapeutic classes, caters to calcium channel blockers, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, renin inhibitors, and others. Several studies have proven that antihypertensive drugs diuretics and beta blockers are far more effective and cost-effective than other types of therapeutic classes. As a result, these are expected to generate significant demand in the worldwide market over the following years.
Various types of anti-hypertensive drugs available in the global industry are primary as well as secondary. Secondary hypertension is the top segment in the market due to faster diagnosis, quicker detection, escalating thyroid cases, kidney problems, chronic alcohol use, adrenal gland tumors, heart ailments, and more. However, the segment can witness a roadblock in the form of patent expiries such as Actelion’s Tracleer (2015), United Therapeutic’s Remodulin (2014), to name a few.
Distribution channels that sell a variety of anti-hypertensive drugs include retail pharmacy, e-commerce websites and online drug stores, hospital pharmacy, and more. E-commerce websites and online drug stores segment is soaring at a faster pace fastest, thanks to the significant internet usage globally along with the accelerated consumption of smartphones and tablets.
Browse Complete Toc :https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347
Regional Study
The key markets for antihypertensive drugs are APAC or Asia Pacific, America, MEA or Middle East & Africa and Europe.
Scaling number of hypertension cases in North America indicate an optimistic outlook for the antihypertensive drugs market. Rising demand for prompt and accurate detection and treatment of the condition, and the establishment of a state-of-the-art healthcare infrastructure in the region also add to the value of the anti-hypertension industry. The sales of orthostatic hypotension drugs have been going up, primarily due to rising number of patients afflicted with low blood pressure.
The APAC market is set to capture the fastest growth rate in the near future, mostly due to the rising awareness about the latest antihypertensive drugs and various treatment options available in the market. Striking expansion rate of the life science sector in India, Malaysia and China has been encouraging the market growth as well. Other growth rendering factors can be the increase in alcohol abuse, surging consumption of toxic substances as well as overexertion. The Indian market for antihypertensive drugs shows a lot of promise, in view of the escalating cases in line with the rising consumption of unhealthy food, lack of healthy and balanced diet, bad sleeping schedules owing to unstable working hours leading to hypertension. Such factors amplify the prevalence rate of several diseases such as stroke, chronic kidney disease, heart failure, peripheral vascular disease and more.
Top Firms
Takeda Pharmaceuticals Company Limited, Ranbaxy Laboratories Limited, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Astra Zeneca plc, Acetelion Ltd, Boehringer Ingelheim, Daiichi Sankyo Company Limited, are some of the top manufacturers of antihypertensive drugs.
Latest News
December 2020
Quantum Genomics, a biotech company specializing in drugs that deal with difficult-to-treat hypertension, has entered a contract with Delpharm, for producing its upcoming clinical series of firibastat tablets.
No comments:
Post a Comment